Related Experiment Videos

Clinical characteristics and outcomes in hypertensive patients of Hispanic descent

Juan M Aranda1, Rafael Calderon, Juan M Aranda

  • 1Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA. arandjm@medicine.ufl.edu

Preventive Cardiology
|April 11, 2008
PubMed

Insights

Hispanic patients face higher hypertension risks despite lower prevalence, due to poor awareness and control. Renin-angiotensin system inhibitors may offer unique benefits for this population.

Area of Science:

  • Cardiovascular Medicine
  • Health Disparities
  • Clinical Pharmacology

Background:

  • Hispanic populations exhibit higher hypertension-related morbidity and mortality despite lower hypertension prevalence.
  • This disparity is linked to reduced hypertension awareness, suboptimal control, and a higher burden of diabetes mellitus and cardiovascular risk factors.
  • Existing antihypertensive therapies show similar efficacy in Hispanic patients, yet clinical trials have historically underrepresented this group.

Purpose of the Study:

  • To highlight the unique challenges and therapeutic considerations for hypertension management in the Hispanic population.
  • To emphasize the potential benefits of renin-angiotensin system inhibitors in this demographic.
  • To advocate for increased inclusion of Hispanic patients in clinical trials for antihypertensive therapies.

Main Methods:

  • Review of existing epidemiological data on hypertension prevalence, morbidity, and mortality in Hispanic populations.
  • Analysis of clinical trial data regarding antihypertensive therapy response in diverse ethnic groups, with a focus on Hispanic representation.
  • Examination of the pharmacological properties of renin-angiotensin system inhibitors, particularly their organ-protective effects.

Main Results:

  • Hispanic patients experience disproportionately higher rates of hypertension-related complications.
  • Lower rates of hypertension awareness and control contribute significantly to this outcome.
  • Renin-angiotensin system inhibitors demonstrate potential for dual benefits: blood pressure reduction and protection against end-organ damage, independent of blood pressure.
  • Hispanic patients respond similarly to antihypertensive treatments, but trial data is limited.

Conclusions:

  • Addressing hypertension in Hispanic populations requires strategies to improve awareness and control.
  • Agents targeting the renin-angiotensin system may be particularly advantageous for Hispanic patients due to their organ-protective effects.
  • Enhanced clinical trial participation for Hispanic individuals is crucial for optimizing hypertension management and reducing health disparities.

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...